Donnerstag, 22. April 2021
Navigation öffnen
Anzeige:
Vectibix
JOURNAL ONKOLOGIE – STUDIE

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Rekrutierend

NCT-Nummer:
NCT02601950

Studienbeginn:
Dezember 2015

Letztes Update:
22.10.2020

Wirkstoff:
Tazemetostat

Indikation (Clinical Trials):
Neoplasms, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Chordoma, Carcinoma, Medullary, Kidney Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Epizyme, Inc.

Collaborator:
-

Kontakt

Studienlocations
(3 von 32)

Children's Hospital Augsburg Klinikum
86156 Augsburg
(Bayern)
GermanyAbgeschlossen» Google-Maps
Massachusetts General Hospital - Cancer Center
02114 Boston
United StatesRekrutierend» Google-Maps
Seattle Children's Hospital
98105 Seattle
United StatesAbgeschlossen» Google-Maps
Metro South Hospital and Health Service via Princess Alexandra Hospital
QLD 4102 Woolloongabba
AustraliaRekrutierend» Google-Maps
Ansprechpartner:
Jennifer Suffolk
E-Mail: jenniferm.suffolk@health.qld.gov.au
» Ansprechpartner anzeigen
McGill University Health Centre - Royal Victoria Hospital
H4A 3J1 Montreal
CanadaAbgeschlossen» Google-Maps
Hospital Pitie Salpetriere
75651 Paris Cedex 13
FranceAbgeschlossen» Google-Maps
Instituto Nazionale Tumori - National Cancer Institute Via Giacomo Venezian
20133 Milano
ItalyRekrutierend» Google-Maps
Ansprechpartner:
Daniela Morrone
E-Mail: daniela.morrone@istitutotumori.mi.it
» Ansprechpartner anzeigen
National Taiwan University Hospital
10002 Taipei City
TaiwanRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts:

Cohort using tazemetostat 800 mg BID

- Cohort 1 (Closed for enrollment): MRT, RTK, ATRT, and selected tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO]

- Cohort 2 (Closed for enrollment): Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement

- Cohort 3 (Closed for enrollment): Other INI1 negative tumors or any solid tumor with an EZH2 gain of function (GOF) mutation, including: epithelioid malignant peripheral nerve sheath tumor (EMPNST), extraskeletal myxoid chondrosarcoma (EMC), myoepithelial carcinoma, other INI1-negative malignant tumors with Sponsor approval (e.g., dedifferentiated chordoma) any solid tumor with an EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma

- Cohort 4 (Closed for enrollment): Renal medullary carcinoma (RMC)

- Cohort 5 (Closed for enrollment): Epithelioid sarcoma (ES)

- Cohort 6 (Opened for enrollment): Epithelioid sarcoma (ES) undergoing mandatory tumor biopsy

- Cohort 7 (Opened for enrollment): Poorly differentiated chordoma (or other chordoma with Sponsor approval)

Cohort using tazemetostat 1600 mg QD

• Cohort 8 (Opened for enrollment): Epitheliod sarcoma

Subjects will be dosed in continuous 28-day cycles. (Note: if treatment with study drug is discontinued prior to completing 2 years, subjects will be followed for a maximum duration of 2 years from start of study drug dosing.) Response assessment will be performed every 8 weeks while on study.

Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Age (at the time of consent/assent): ≥18 years of age

2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 NOTE: If subject is unable to walk due to paralysis, but is mobile in a wheelchair subject is considered to be ambulatory for the purpose of assessing their performance status.

3. Has provided signed written informed consent

4. Has a life expectancy of >3 months

5. Has a malignancy:

- For which there are no standard therapies available (Cohorts 1, 3, 4 and 5)

- That is relapsed or refractory after treatment with an approved therapy(ies), defined as metastatic or non-resectable, locally advanced disease that has previously been treated with and progressed following approved therapy(ies) (Cohort 2)

- That has progressed within 6 months prior to study enrollment (Cohort 5 Expansion, Cohort 6 and Cohort 8 ONLY)

6. Has a documented local diagnostic pathology of original biopsy confirmed by a Clinical Laboratory Improvement Amendments (CLIA/College of American Pathologists (CAP) or equivalent laboratory certification

7. For Cohort 1 (rhabdoid tumors only), the following test results must be available by local laboratory: morphology and immunophenotypic panel consistent with rhabdoid tumors, and loss of INI1 or SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 or SMARCA4 loss or mutation when INI1 or SMARCA4 IHC is equivocal or unavailable

8. For Cohort 2 (subjects with relapsed/refractory synovial sarcoma only), the following tests must be available by local laboratory: Morphology consistent with synovial sarcomas, and cytogenetics or fluorescence in situ hybridization (FISH) and/or molecular confirmation (e.g., DNA sequencing) of SS18 rearrangement t(X;18)(p11;q11)

9. For Cohort 3, 4, 5, 7 and 8 (subjects with INI1-negative/aberrant tumors or any solid tumor with EZH2 GOF mutation only), the following test results must be available by local laboratory: Morphology and immunophenotypic panel consistent with INI1-negative tumors (not applicable for solid tumors with EZH2 GOF mutation), and loss of INI1 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 loss or mutation when INI1 IHC is equivocal or unavailable, or molecular evidence of EZH2 GOF mutation

10. For Cohort 6 (subjects with epithelioid sarcoma undergoing optional tumor biopsy):

- Morphology and immunophenotypic panel consistent with epithelioid sarcoma (e.g., CD34, EMA, Keratin, and INI1)

- If providing optional biopsy: Willingness to provide informed consent to undergo pre- and post-dose biopsy

11. Has all prior treatment (I.e. chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ≤Grade 1 per CTCAE version 4.0.3 or are clinically stable and not clinically significant, at time of enrollment.

12. Prior anti-cancer therapy(ies), if applicable, must be completed according to the criteria below:

- Chemotherapy: cytotoxic (At least 14 days since last dose of chemotherapy prior to first dose of tazemetostat)

- Chemotherapy: nitrosoureas (At least 6 weeks since last dose of nitrosoureas prior to first dose of tazemetostat)

- Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least 14 days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)

- Monoclonal antibody(ies) (At least 28 days since the last dose of any monoclonal antibody prior to first dose of tazemetostat)

- Immunotherapy (e.g. tumor vaccine) (At least 42 days since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)

- Radiotherapy (RT) (At least 14 days from last local site RT prior to first dose of tazemetostat/At least 21 days from stereostatic radiosurgery prior to first dose of tazemetostat/At least 12 weeks from craniospinal, ≥50% radiation of pelvis, or total body irradiation prior to first dose of tazemetostat)

- High dose therapy with autologous hematopoietic cell infusion (At least 60 days from last infusion prior to first dose of tazemetostat)

- Hematopoietic growth factor (At least 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat)

13. Has sufficient tumor tissue (slides or blocks) available for central confirmatory testing of IHC and/or cytogenetics/FISH and/or DNA mutation analysis (required for study entry but enrollment based on local results)

14. Has measurable disease based on either RECIST 1.1 for solid tumors or RANO for CNS tumors

15. Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic function as defined by criteria below:

- Hematologic (BM Function):

- Hemoglobin ≥9 mg/dL

- Platelets ≥100,000/mm^3 (≥100x10^9/L)

- ANC ≥1,000/mm^3 (≥1.0x10^9/L)

- Hematologic (Coagulation Factors):

- INR/PT₫ <1.5 ULN

- PTT>1.5 ULN

- Renal Function:

- Serum creatinine ≤1.5 x ULN

- Hepatic Function:

- Total bilirubin <1.5 x ULN(Eligibility can be determined by conjugated or total bilirubin)

- AST and ALT <3 x ULN NOTE: Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the Investigator may retest the subject and the subsequent within range screening result may be used to determine the subject's eligibility.

16. For subjects with CNS Tumors only, subject must have seizures that are stable, not increasing in frequency or severity and controlled on current anti-seizure medication(s) for a minimum of 21 days prior to the planned first dose of tazemetostat NOTE: Subjects may receive glucocorticoids (at stable or tapering dose) to control CNS symptoms prior to enrollment; however, subjects should receive a stable or tapering dose for at least 7 days prior to planned first dose of tazemetostat

17. Has a shortening fraction of >27% or an ejection fraction of ≥50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class ≤2

18. Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec

19. Female subjects of childbearing potential must:

- Have a negative beta-human chorionic gonadotropin (β-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of tazemetostat (urine or serum test is acceptable however, positive urine tests must be confirmed with serum testing), and

- Agree to use effective contraception, as defined in Section 8.6.1, from a minimum of 7 days prior to first dose until 6 months following the last dose of tazemetostat and have a male partner who uses a condom, or

- Practice true abstinence (when this is in line with the preferred and usual lifestyle of the subject, see Section 8.6.1), or Have a male partner who is vasectomized

20. Male subjects with a female partner of childbearing potential must:

- Be vasectomized, or

- Agree to use condoms as defined in Section 8.6.2, from first dose of tazemetostat until 3 months following the last dose of tazemetostat, or

- Have a female partner who is NOT of childbearing potential

Exclusion Criteria:

1. Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2 (EZH2)

2. Has participated in another interventional clinical study and received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the planned first dose of tazemetostat

3. Has known active CNS or any leptomeningeal metastasis of primary extra-cranial tumor. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging 4 weeks prior to the first dose of study drug and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and are on stable or tapering doses of steroids for at least 7 days prior to first dose of study drug. NOTE: Subjects with asymptomatic brain metastases found on screening MRI may be entered into the study without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant.

4. Has had a prior malignancy other than the malignancies under study - EXCEPTION: A subject who has been disease-free for 5 years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible

5. Has had major surgery within 3 weeks prior to enrollment Note: Minor surgery (e.g., minor biopsy of extracranial site central venous catheter placement, shunt re-vision) is permitted 3 weeks prior to enrollment.

6. Has Thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE 4.03 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS). Has abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and MPN (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing.

NOTE: Bone marrow aspirate/biopsy will be conducted following abnormal peripheral blood smear morphology assessment conducted by central laboratory. Cytogenetic testing and DNA sequencing will be conducted following an abnormal result of bone marrow aspirate/biopsy.

7. Has a prior history of T-LBL /T-ALL

8. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study

9. Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment

10. Is currently taking any prohibited medication(s)

11. Has an active infection requiring systemic treatment

12. Is immunocompromised (i.e. has congenital immunodeficiency), including subjects known history of infection with human immunodeficiency virus (HIV)

13. Has known active infection with hepatitis B virus or hepatitis C virus

- Note - Subjects with a history of hepatitis B or C with normal ALT and undetectable HBV DNA or HCV RNA are eligible for this study

14. Has had a symptomatic venous thrombosis within 2 weeks prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis >2 weeks prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study

15. For subjects with CNS involvement (primary tumor or metastatic disease), have any active bleeding or new intratumoral hemorrhage of more than punctuate size of screening MRI obtained within 14 days of starting study drug or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents

16. Has known hypersensitivity to any of the component of tazemetostat or other inhibitor(s)of EZH2

17. Is unable to take oral medications, or has a malabsorption syndrome or any uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that would limit compliance with study requirements.

18. Has an uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements.

19. For female subjects of childbearing potential: Is pregnant or nursing

20. For male subjects: Is unwilling to adhere to contraception criteria from time of enrollment in the study to at least 3 months after last dose of tazemetostat.

Studien-Rationale

Primary outcome:

1. Number of subjects with objective response using disease appropriate standardized response criteria (Time Frame - Assessed every 8 weeks for duration of study participation which is estimated to be 24 months)

2. Progression-free survival (PFS) rate for Cohort 2 (Relapsed/Refractory Synovial Sarcoma) (Time Frame - 16 weeks of treatment):
The number of subjects with CR, PR, or stable disease (SD) at 16 week assessment

3. Assess the effects of tazemetostat on tumor immune priming for Cohort 6 (Time Frame - Through study completion, an average of 2 years)

4. Assess the safety and tolerability of tazemetostat 1600 mg QD for Cohort 8 (Time Frame - Through study completion, an average of 2 years)

Secondary outcome:

1. Duration of response in subjects in Cohorts 1, 2, 3, 4, 5, 6 and 7 and in Cohorts 1, 3, 4, 5, 6 and 7 combined for subjects achieving a complete response (CR) and partial response (PR) following oral administration of tazemetostat 800 mg BID (Time Frame - Assess every 8 weeks for duration of study participation which is estimated to be 24 months)

2. Disease control rate (DCR) in subjects with epithelioid sarcoma (Cohort 5) and epithelioid sarcoma undergoing mandatory biopsy (Cohort 6) following oral administration of tazemetostat 800 mg BID (Time Frame - 32 weeks of treatment):
The number of subjects with confirmed CR, PR or SD at 32 week assessment

3. Overall response rate ORR for Cohort 2 (relapsed/refractory synovial sarcoma) and Cohort 6 (epithelioid sarcoma undergoing mandatory biopsy) following oral administration of tazemetostat 800 mg BID (Time Frame - Assessed every 8 weeks for duration of study participation which is estimated to be 24 months):
ORR (confirmed CR+PR, RECIST 1.1)

4. PFS for each cohort (Time Frame - 24, 32 and 56 weeks of treatment):
The time from date of first dose of study treatment to the earlier of the date of first documented disease progression or date of death due to any cause

5. OS for each cohort (Time Frame - 24, 32 and 56 weeks of treatment):
The time from the date of the first dose of study treatment to the date of death due to any cause

6. Incidence of treatment-emergent adverse events as a measure of safety and tolerability (Time Frame - Adverse events assessed from first dose through 30 days post last dose)

7. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Cmax (Time Frame - Days 1 and 15)

8. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Tmax (Time Frame - Days 1 and 15)

9. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): AUC(0-t) (Time Frame - Days 1 and 15)

10. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): AUC(0-12) (Time Frame - Days 1 and 15)

11. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): t1/2 (Time Frame - Days 1 and 15)

12. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): CL/F (Time Frame - Days 1, 15, 29, 43, and 57)

13. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Vd/F (Time Frame - Days 1, 15, 29, 43, and 57)

14. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Ka (Time Frame - Days 1, 15, 29, 43, and 57)

15. Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Ctrough (Time Frame - Days 29, 43 and 57)

16. Investigate the pharmacodynamics (PD) effects of tazemetostat in tumor tissue (Time Frame - At week 8):
IHC assessments of changes in the level of H3K27-Me3 following tazemetostat dosing

17. Duration of response in subjects with epithelioid sarcoma in Cohort 8 at 1600 mg QD. (Time Frame - Assess every 8 weeks for duration of study participation which is estimated to be 24 months)

18. Disease control rate (DCR) in subjects with epithelioid sarcoma (Cohort 8) following oral administration of tazemetostat 1600 mg QD (Time Frame - 32 weeks of treatment):
The number of subjects with confirmed CR, PR or SD at 32 week assessment

19. Overall response rate ORR for subjects with epithelioid sarcoma (Cohort 8) following oral administration of tazemetostat 1600 mg QD (Time Frame - Assessed every 8 weeks for duration of study participation which is estimated to be 24 months):
ORR (confirmed CR+PR, RECIST 1.1)

Geprüfte Regime

  • Tazemetostat (EPZ-6438 / E7438 / ):
    Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Junge Krebspatienten: Ausbildung und Familie, aber auch Angst und Schmerzen
Junge+Krebspatienten%3A+Ausbildung+und+Familie%2C+aber+auch+Angst+und+Schmerzen
© pathdoc / Fotolia.com

„Ich hatte große Träume für mein Leben, jetzt denke ich oft viel, viel kurzfristiger“, sagt die 25-jährige Studentin Mia*, die vor anderthalb Jahren an Krebs erkrankte. Nach der Diagnose musste sie ihr Studium unterbrechen, ihre Familienplanung in Frage stellen und auch mit ihrem Freundeskreis einen neuen Umgang finden. Sie ist eine von rund 15.000 jungen Menschen, die jährlich im Alter von 18 bis 39 Jahren...

Die P4-Medizin – Krebstherapie der Zukunft?
Die+P4-Medizin+%E2%80%93+Krebstherapie+der+Zukunft%3F
© Fotolia / psdesign1

Die Versorgung von krebskranken Menschen befindet sich in einem grundlegenden Wandel. Die Entwicklung neuer diagnostischer Methoden und individueller Therapien verändert die onkologische Medizin, wie wir sie bisher kennen. Das jüngst gewonnene Wissen über den Krebs und seine molekularbiologische Vielfalt verlangt nach neuen Antworten. In dem vom amerikanischen Biomediziner Leroy Hood geprägten Konzept der P4-Medizin wird...

Das Klinikum Herford unterstützt Krebs-Patienten und Patientinnen mit digitalem Therapie-Assistenten
Das+Klinikum+Herford+unterst%C3%BCtzt+Krebs-Patienten+und+Patientinnen+mit+digitalem+Therapie-Assistenten+
© adam121 / Fotolia.de

Das Klinikum Herford bietet seinen gynäkologischen Krebs-Patientinnen ab sofort einen digitalen Therapiebegleiter an, der sie im Umgang mit der Erkrankung unterstützt. Die Smartphone-App MIKA begleitet Betroffene durch die Behandlung und hilft ihnen unter anderem mit Gesundheitsmonitoring und psychosozialem Coaching. Mit dem neuen digitalen Assistenten geht das Klinikum Herford einen weiteren Schritt, um Erkrankte zu mehr...